Researchers have identified various factors associated with mortality following a diagnosis with the COVID-19 virus among recipients of allogeneic and autologous HCT.
A team of investigators sought to evaluate outcomes following combination treatment with eprenetapopt and azacitadine in TP53-mutant myelodysplastic syndromes, as well as in oligoblastic acute myeloid leukemia.
Among patients with HIV-associated Burkitt lymphoma, intensive regimens containing rituximab may be linked to favorable survival outcomes.
Initial treatment of mantle cell lymphoma with lenalidomide and rituximab may result in significant complete response rates and durable lengths of remission.
Investigators assessed mortality rates and other outcomes in patients with hematologic malignancies and COVID-19 infection.
Among patients with blood cancers, genetic variant profiles may negatively affect allo-HSCT outcomes including leukemia-free survival and acute GVHD.
Study results presented at the annual meeting of the American Society of Hematology suggest that the estimated 4-year mortality rate among patients with polycythemia vera is more than 10%, and that causes of death vary.
A geno-clinical model used mutational data and peripheral blood counts to accurately distinguish myelodysplastic syndromes from other myeloid malignancies.
There might be notable variations among hematology, oncology, and bone marrow transplant practitioners when treating thrombotic events in children with leukemia.
The Ferrara criteria are widely used to identify patients with AML who are most suitable for intensive chemotherapy, though the accuracy is unknown.
